ALFA FinderNSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.67
- Market cap
- ₹125.2 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 51.6×Sector 43.8×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Other other announcement announcements
All →Neueon Corporation Other Announcement
Neueon Corporation's members approved amendments to its Articles of Association via postal ballot, now approved by the Registrar of Companies. The amendment allows the Board to make multiple calls on partly paid shares.
Leapfrog Engineering Services Other Announcement
Leapfrog Engineering received a Trade Mark registration certificate for building construction services in Class 37. The registration discloses no monetary value or business impact.
Quest Laboratories Other Announcement
Quest Laboratories reported no deviation in IPO fund utilisation for the half year ended September 2026. Its statement was reviewed by the Audit Committee.
Vinyas Innovative Technologies Other Announcement
Vinyas Innovative filed CRISIL's monitoring agency report for the quarter ended 30 September 2026. It reports no deviation from objects for its preferential warrant issue proceeds.
Parag Milk Foods Other Announcement
Sixth Sense India Opportunities III sold 43,842 shares on NSE for about Rs 1.45 Crore. Its stake fell from 1.44% to 1.40%.
- Value
- ₹1.45 Cr
Titan Intech Other Announcement
Titan Intech submitted the Acuité monitoring agency report on its rights issue proceeds for the quarter ended September 30, 2026. The report finds no deviation from the offer objects.